Darolutamide Cuts Prostate Cancer Metastasis Risk by 58% in DASL-HiCaP Phase 3 — What the Data Shows
Darolutamide DASL-HiCaP Trial Cuts Prostate Cancer Metastasis Risk by 58%, Phase 3 Data Shows Men with high-risk localized prostate cancer facing radiotherapy now have concrete new phase 3 data to raise with